Bortemap 2mg Injection is a vital medication used in the treatment of multiple myeloma and mantle cell lymphoma. Its active ingredient, Bortezomib, belongs to a class of drugs known as proteasome inhibitors. Bortezomib works by blocking the action of proteasomes, which are protein complexes within cells responsible for breaking down unneeded or damaged proteins. By inhibiting proteasomes, Bortezomib leads to an accumulation of abnormal proteins within cancer cells, ultimately triggering cell death (apoptosis). This targeted action helps to control the growth and spread of these specific types of cancer.
The typical dosage and administration of Bortemap 2mg Injection are determined by a healthcare professional based on the patient’s condition, response to treatment, and other individual factors. It is administered intravenously or subcutaneously. Common side effects may include fatigue, gastrointestinal issues (nausea, vomiting, diarrhea, constipation), peripheral neuropathy (numbness, tingling, pain in hands and feet), and a decrease in blood cell counts. Patients should inform their doctor about any pre-existing medical conditions, especially nerve problems, heart conditions, or liver/kidney issues, before starting treatment. Bortemap 2mg Injection should be stored at room temperature, protected from light and moisture, and kept out of reach of children.
